Albany, NY -- (SBWIRE) -- 08/30/2019 -- Chronic Neuropathic Pain Market Insights, Epidemiology and Market Forecast-2028
1. Chronic Neuropathic Pain prevalence in a general Japanese population was 3.2%, which was lower than the 8.8% found in the United States and the 8.2% found in the United Kingdom.
2. Over 1 million people in Japan had chronic pain with neuropathy in 2013. The main conditions or diseases identified were postherpetic neuralgia (PHN), trigeminal neuralgia (TN), painful diabetic peripheral neuropathy (PDPN), and glossopharyngeal neuralgia (GN).
3. In the United Kingdom, diabetic neuropathy prevalence was 26.4 % among diabetes type 2 patients.
DelveInsight launched a new report on Chronic Neuropathic Pain Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Chronic Neuropathic Pain market report covers a descriptive overview and comprehensive insight of the Chronic Neuropathic Pain epidemiology and Chronic Neuropathic Pain market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Neuropathic Pain market report provides insights on current and emerging therapies.
3. Chronic Neuropathic Pain market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Neuropathic Pain market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Neuropathic Pain market.
Request for sample pages
"Chronic Neuropathic Pain was more common in females as compared to males and has reached its peak between 70 and 79 years of age."
The first goal Chronic Neuropathic Pain treatment is to recognise the underlying disease or condition, which causes the pain and treat it, if possible. The most common neuropathic pain treatments include Over-the-counter pain medication, Opioid pain medications, Antidepressant drugs, Anticonvulsants. The first-line medications are the gabapentinoid class of anticonvulsants. Tramadol is a second-line medication in Chronic Neuropathic Pain treatment and is of benefit in diabetic neuropathy and mixed Neuropathic Pain syndromes. It is a weak ?-opioid receptor agonist and weak serotonin noradrenaline reuptake inhibitors (SNRI). Cannabinoids have been shifted from a fourth-line to a third-line Chronic Neuropathic Pain treatment option. The cannabinoid is used for Neuropathic Pain from HIV, diabetic neuropathy, posttraumatic or postsurgical Neuropathic Pain, and mixed central and peripheral Neuropathic Pain states.
Over-the-counter pain medication such as Nonsteroidal anti-inflammatory drugs (NSAIDs) is sometimes used for neuropathic pain treatment. Prescription medicines such as opioid pain medications can help some people, but they may not reduce pain from neuropathic pain as they reduce other types of pain. Antidepressant drugs have shown great promise in treating Chronic Neuropathic Pain symptoms. Two common types of antidepressant medications are prescribed to people with this condition. They are tricyclic antidepressants and serotonin noradrenaline reuptake inhibitors. These may treat both the pain and symptoms that is caused by chronic pain. Anti-seizure medications and anticonvulsants are sometimes used for neuropathic pain treatment. Gabapentinoids are most commonly used for neuropathic pain treatment. The implantable device is an invasive procedure which requires a surgeon to implant a tool in the body. Some methods are used in the brain, and some are used in the spine. These devices are typically used only in individuals who have not responded well to other treatment options. Additionally, there are a variety of complementary therapies that can help relieve neuropathic pain. These therapies are commonly used in combination with medications and include Physical or occupational therapy, Relaxation therapy etc.
The dynamics of Chronic Neuropathic Pain market is expected to change in the upcoming years due to the diagnosis methodologies, raising awareness of the improvement of the disease, and incremental healthcare spending across the world, and also expected the launch of emerging therapies during the forecast period of 2019-2028.
The launch of the emerging therapies is expected to significantly impact the Chronic Neuropathic Pain treatment scenario in the upcoming years:-
Drugs covered
1. CNTX-0290
2. CNTX-2022
3. AP-325
4. Omnitram
And many others
The key players in Chronic Neuropathic Pain market are:
1. Centrexion Therapeutics
2. Algiax Pharmaceuticals
3. Syntrix Biosystems
And many others
Table of contents
1. Report Introduction
2. Chronic Neuropathic Pain Market Overview at a Glance
3. Chronic Neuropathic Pain Disease Background and Overview
4. Chronic Neuropathic Pain Epidemiology and Patient Population
5. Chronic Neuropathic Pain Country Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.United Kingdom
6. Chronic Neuropathic Pain Treatment & Medical Practices
7. Chronic Neuropathic Pain Marketed Drugs
7.1. Neurontin: Pfizer
7.2. Lyrica: Pfizer
8. Chronic Neuropathic Pain Key Emerging Therapies
8.1. CNTX-0290: Centrexion Therapeutics
8.2. AP-325: Algiax Pharmaceuticals
9. Chronic Neuropathic Pain Market Size
10. 7MM Chronic Neuropathic Pain Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
11. Market Drivers
12. Market Barriers
13. Appendix
14. Chronic Neuropathic Pain Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight